Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction

[1]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[2]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[3]  Sanjiv J. Shah,et al.  Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial , 2021, European journal of heart failure.

[4]  P. Ponikowski,et al.  Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. , 2021, Journal of cardiac failure.

[5]  K. Witte,et al.  Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction , 2021, Open Heart.

[6]  P. Ponikowski,et al.  Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure , 2021, European journal of heart failure.

[7]  P. Ponikowski,et al.  Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry , 2021, ESC heart failure.

[8]  G. Fonarow,et al.  Heart Failure With Mid-range Ejection Fraction , 2020, Current Heart Failure Reports.

[9]  Akshay S. Desai,et al.  Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure , 2019, Circulation.

[10]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[11]  G. Filippatos,et al.  Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial , 2019, European journal of heart failure.

[12]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[13]  J. H. Patterson,et al.  Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[14]  P. Ponikowski,et al.  Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2019, European journal of heart failure.

[15]  D. Pennell,et al.  Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial , 2019, The Lancet.

[16]  Thomas A. Slater,et al.  Prospective evaluation and long term follow up of patients referred to secondary care based upon natriuretic peptide levels in primary care. , 2018, European heart journal. Quality of care & clinical outcomes.

[17]  S. Solomon,et al.  Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum , 2018, European journal of heart failure.

[18]  L. Lund.  Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM. , 2018, Cardiac failure review.

[19]  M. Kearney,et al.  Socioeconomic deprivation and mode-specific outcomes in patients with chronic heart failure , 2018, Heart.

[20]  Roland A Matsouaka,et al.  Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. , 2017, Journal of the American College of Cardiology.

[21]  M. Kearney,et al.  Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes , 2017, Diabetes Care.

[22]  T. Shiroto,et al.  Characterization of heart failure patients with mid‐range left ventricular ejection fraction—a report from the CHART‐2 Study , 2017, European journal of heart failure.

[23]  Gianluigi Savarese,et al.  A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction , 2017, European journal of heart failure.

[24]  Akshay S. Desai,et al.  Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. , 2016, European heart journal.

[25]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[26]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[27]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[28]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[29]  G. Fonarow,et al.  Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. , 2009, Journal of the American College of Cardiology.

[30]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[31]  B. Massie,et al.  β-Blocker dosing in community-based treatment of heart failure , 2007 .

[32]  P. Poole‐Wilson,et al.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey , 2005 .

[33]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[34]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[35]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[36]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[37]  A. Hoes,et al.  Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry. , 2019, JACC. Heart failure.

[38]  B. Massie,et al.  Beta-blocker dosing in community-based treatment of heart failure. , 2007, American heart journal.